Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)

NCT02293603 is registered in ClinicalTrials.gov with Capricor Inc. as lead sponsor.

NCT NCT02293603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02293603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)
Lead sponsor
Capricor Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2014
Completion date
April 30, 2020
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dilated cardiomyopathy (dcm), heart failure, ischemic cardiomyopathy, nonischemic cardiomyopathy